News
At the halfway mark last year, 97 layoff rounds were reported, marking a 32% year-over-year increase for the first half of ...
The FDA has cleared its first cuffless blood pressure monitor that will be available over-the-counter, with the Hilo ...
Taiho-developed TAS-205 is designed to selectively inhibit hematopoietic prostaglandin D synthase (HPGDS), an enzyme related ...
Cargo will mark the latest in a string of acquisitions for the deal-hungry Concentra. So far this year, Concentra has signed ...
At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...
KJ Muldoon recently made history by becoming the first patient to receive a personalized CRISPR gene therapy, designed specifically for the genetic mutations causing his rare metabolic disease. | KJ ...
Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which obtained a groundbreaking FDA clearance late last year. | LumiThera's approach ...
Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.
Headlands Research, a clinical trial site network with locations across the U.S. and Canada, has made its first step into the ...
Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...
Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...
CSL will consolidate its R&D teams around six sites located in biotech hubs as the company looks to boost external ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results